enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Androgen deprivation therapy - Wikipedia

   en.wikipedia.org/wiki/Androgen_deprivation_therapy

   Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...

3. Management of prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Management_of_prostate_cancer

   Abiraterone acetate was FDA approved in April 2011 for treatment of castration-resistant prostate cancer for patients who have failed docetaxel therapy. Abiraterone acetate inhibits an enzyme known as CYP17, which is used in the body to produce testosterone.

4. Opevesostat - Wikipedia

   en.wikipedia.org/wiki/Opevesostat

   Opevesostat is an investigational new drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). [1] It is a non-steroidal, selective inhibitor of CYP11A1 (cholesterol side-chain cleavage enzyme) [2] discovered by Orion Corporation and currently undergoing clinical development by Merck & Co., Inc. Opevesostat's mechanism of action involves suppressing ...

5. Prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Prostate_cancer

   Eventually cancer cells can grow resistant to this treatment. This most-advanced stage of the disease, called castration-resistant prostate cancer, is treated with continued hormone therapy alongside the chemotherapy drug docetaxel. Some tumors metastasize (spread) to other areas of the body, particularly the bones and lymph nodes.

6. Sipuleucel-T - Wikipedia

   en.wikipedia.org/wiki/Sipuleucel-T

   Sipuleucel-T is indicated for the treatment of metastatic, asymptomatic or minimally symptomatic, metastatic castrate-resistant hormone-refractory prostate cancer (HRPC). ). Other names for this stage are metastatic castrate-resistant (mCRPC) and androgen independent (AI) or (A

7. Comparison of bicalutamide with other antiandrogens

   en.wikipedia.org/wiki/Comparison_of_bicalutamide...

   Bicalutamide monotherapy has been reported to be roughly equivalent in effectiveness compared to GnRH analogues and castration in the treatment of prostate cancer. [ 4 ] [ 78 ] [ 82 ] A meta-analysis concluded that there is a slight effectiveness advantage for GnRH analogues/castration, but the differences trended towards but did not reach ...